Perspective Therapeutics, Inc. (CATX) stock
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Earnings
Perspective Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Perspective Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 15, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | $20.00K | – | -$0.27 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026after the close | $81.00K | -73.0% | -$0.22 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 4, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 16, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 20, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025before the open | $300.00K | 0.0% | -$0.29 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 26, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $400.00K | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024after the close | $300.00K | – | -$0.02 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024before the open | $300.00K | – | -$0.02 | Release |
| Q4 FY2022ended Jun 30, 2022 | Sep 28, 2022after the close | $2.50M | – | -$0.01 | Release |
| Q3 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $2.91M | – | -$0.01 | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 8, 2022after the close | $2.82M | – | -$0.01 | Release |
| Q1 FY2022ended Sep 30, 2021 | Nov 10, 2021after the close | $2.56M | – | -$0.02 | Release |
| Q4 FY2021ended Jun 30, 2021 | Sep 21, 2021after the close | – | – | – | Filing |
| Q3 FY2021ended Mar 31, 2021 | May 13, 2021after the close | – | – | – | Filing |
| Q2 FY2021ended Dec 31, 2020 | Feb 3, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Sep 30, 2020 | Nov 10, 2020after the close | – | – | – | Filing |
| Q4 FY2020ended Jun 30, 2020 | Sep 17, 2020after the close | – | – | – | Filing |
| Q3 FY2020ended Mar 31, 2020 | May 12, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Dec 31, 2019 | Feb 11, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Sep 30, 2019 | Nov 12, 2019after the close | – | – | – | Filing |
| Q4 FY2019ended Jun 30, 2019 | Sep 24, 2019after the close | – | – | – | Filing |
| Q3 FY2019ended Mar 31, 2019 | May 9, 2019after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Perspective Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Perspective Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Perspective Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
- News
- News
- News
- News
- News
- News
- News
- Results
- Results
See a number that looks wrong?